Kantarjian et al53 assessed the efficacy and security of dasatinib, as when compared with imatinib, for the first-line cure of CML-CP. 5 hundred and nineteen people with recently diagnosed CML-CP ended up randomly assigned to get dasatinib in a dose of a hundred mg after day by day (259 people) https://canagliflozin21098.estate-blog.com/28354991/the-2-minute-rule-for-brr2-in-3